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Abstract--The human lymphoblast line MGL8 was treated with HAT and 
subsequently "mutagenized" with EMS (200 l.~g/ml) to give 15% survival, 
and 6-thioguanine-resistant cells were selected by cloning in soft agarose 
containing the drug (1 ixg/ml). Eighteen sublines of indePendently derived 
resistant clones were isolated and studied in detail. One subline had a low 
residual HGPRT activity of  about 1% of  the parental cells. The HGPRT 
of this subline had a higher Kmfor PRPP, was more sensitive to heat, and 
was degraded faster by trypsin than the enzyme in extracts of  MGL8 
cells. This resistant subline and three others contained CRM levels o f l -  
38%, compared to the wild-type, so they probably represent true 
structural mutants of  the HGPRT gene. All the variants maintained the 
karyotype of  the parental line (46, XY, 6p-). 
I N T R O D U C T I O N  
Diploid cell lines with stable karyotypes are advantageous for genetic 
studies, since variation in aneuploid cells may reflect C~nges other than 
point mutations, such as rearrangement or loss of chromosomal material 
or perhaps epigenetic phenomena, which are PoOrly understood at 
present (1-5). The growth characteristics of human lymphoblast lines in 
culture (6) make these cells a favorable model for mu~agenesis studies 
aimed at investigating the molecular genetics of enzymes. Sato et al. (7), 
Lever et al. (8), and Nyoromi et al. (9) have reported the selection of 
HGPRT (hypoxanthine guanine phosphoribosyltransferase)-deficient 
variants from human lymphoblast lines that have normal HGPRT activity. 
The purpose of this paper is to describe the diverse biochemical and im- 
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munochemical characteristics of 18 6TG (6-thioguanine)-resistant clonal 
lines derived from a human lymphoblast line after "mutagenesis" with 
EMS (ethylmethane sulfonate). All the cells in all these variant sublines 
maintained the parental karyotype of 46, XY, 6p-. Four variants 
contained significant amounts of CRM and most likely represent true 
mutants in the structural gene for HGPRT. 
METHODS 
Cell Cultures 
The human lymphoblast cell line MGL8 was established by Dr. H. R. 
Zielke from a blood sample from a 28-yr-old healthy male donor, accord- 
ing to the method of Beratis and Hirschhorn (10). The cells were main- 
tained in static suspension culture in Roswell Park Memorial Institute 
1640 medium (GIBCO) supplemented with 15% (v/v) fetal calf serum 
(MBA), and were incubated at 37~ in a 5% (v/v) CO~ atmosphere. The 
cultures were passed twice weekly at 2x l0 s cells/ml, and showed a dou- 
bling time of 26-30 hr with a final yield of 1.5 x 106 cells/ml. Cell numbers 
were determined with a Coulter Electronics model ZBI counter. All the 
cultures were periodically tested and found free of mycoplasma contami- 
nation by the culture method (11) and by the uridine/uracil incorporation 
ratio (12). The MGL8 cells are diploid except for a deletion in the short 
arm of chromosome No. 6, which was acquired after several months in 
culture and is present in all cells, providing a useful marker. 
Cloning in Soft Agarose 
Cells were mixed in 2 ml medium containing 0.22% agarose (Marine 
Colloids) and layered over 2.5 ml of a 0.24% agarose medium separating 
layer in a 60-mm petri dish (7). Monolayers of diploid fibroblasts from a 
patient with Lesch-Nyhan syndrome were used as the "feeder" layer. 
Treatment with Mutagen 
To determine the response of the wild-type MGL8 cells to mutagen 
treatment, exponentially growing cells were exposed to varying 
concentrations of EMS in culture medium for 20 hr. The cells were then 
counted, washed in fresh warm RPMI 1640 medium, and resuspended in 
fresh medium to the initial volume. The growth of the culture was 
followed by daily counts. This was important for maximal recovery of 
variants. Cells treated with 200 ~g/ml of EMS showed 15-20% survival 
immediately after treatment, but they needed 9-12 days to completely 
recover, at which time the cloning efficiency finally reached a level equal 
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to that of untreated control cells. The cloning efficiency of MGL8 varied 
in different experiments between 15% and 29% but was consistant in all 
the replicate plates (at least four) used in each experiment. 
HGPRT Activity 
Cell Extracts. Logarithmically growing cells were washed two times 
in cold PBS by centrifugation, and then resuspended in 0.01 M phosphate 
(K § buffer, pH 6.8, containing 0.25 M sucrose. The cell suspensions 
containing 10 r MGL8 cells/ml or 108 mutant cells/ml were lysed by freeze- 
thawing three times in a dry-ice-ethanol bath. Following a 30-min cen- 
trifugation at 24,000g, the supernatants were diluted in 10 -2 M phosphate 
buffer, pH 6.8, containing sucrose (0.25 M) and bovine serum albumin 
(BSA) (1 mg/ml). Dilution ratios were 1:10 for the normal extracts and 1:2 
for those of the resistant cells. All extracts were stored at -70~ and 
thawed immediately before the assay for enzyme activity. Protein 
concentrations in the extracts were determined by the method of Lowry 
et al. (13). 
Enzyme Assay. HGPRT activity was determined by a radiochemical 
assay. The final reaction mixture of 50/zl contained 50 mM potassium 
phosphate buffer, pH 7.4, 5 mM MgCh, I mM PRPP, 20 /zm 14C- 
hypoxanthine (12-50/x Ci/m mole), and 25 ~1 of the diluted cell extracts. 
The reaction mixtures were incubated at 37~ Incubation time was 15 
min for the normal lysate and from 45 rain to 2 hr for the lysates of the 
resistant cells. The reaction was stopped by the addition of 5/zl of 0.27 M 
EDTA and rapid chilling to 0-2~ A 25-/A aliquot of the reaction mixture 
was spotted on a DEAE disk (Whatman DE81). The disks were air-dried, 
washed twice in 1 mM ammonium formate, once in water, and finally in 
70% ethanol. Then the disks were dried under a drying lamp, and ra- 
dioactivity was counted in a liquid scintillation counter. Enzyme activity 
was also assayed at pH 10.0 (100 mM glycine-NaOH) (Nash and Johnson, 
unpublished) or in the presence of 33 mM MgTTP to inhibit nucleotidase 
activity. In this case products were separated by high-voltage elec- 
trophoresis. Enzyme activities were found to be essentially identical 
under these different assay conditions. 
Determination of Immunologically Cross-Reacting Material (CRM) 
Cell Extracts. Cells (4.6-6.5 x 108) stored at -70~ were extracted 
at 4~ with 0.6-0.7 ml 0.05 M potassium phosphate, pH 7.4, by freeze- 
thawing twice in a dry-ice-acetone bath. Lysates were centrifuged for 20 
min at 10,000 g, and the supernatants were dialyzed against 400 volumes 
of the same buffer at 4~ overnight with one change of buffer. Dialyzed 
cell extracts were stored at -70~ until the time of assay. 
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The immunoprecipitation-inhibition assay was performed in 50 /xl 
reaction mixtures containing 2.75 /xg of wild,type lymphoblast extract 
protein plus varying amounts of wild-type or HGPRT-deficient cell ex- 
tract, 25/xl of rabbit anti-HGPRT serum (15) diluted 1/512 (the antiserum 
was diluted with nonimmune serum diluted 1/128), 0.15 M NaC1, 0.05 M 
potassium phosphate, pH 7.4, and 1.5 mM Mg PRPP. After incubation at 
37~ for 30 min and then at 4~ for 2-4 hr, 25/zl of goat antirabbit IgG 
serum diluted 88 was added, and the reaction mixtures were incubated at 
37~ for 30 min and 4~ for 12-18 hr. The immunochemical precipitate 
was collected by centrifugation at 1,000 g for 20 min at 4~ and the 
supernatant was assayed for HGPRT activity. Enzyme activity 
contributed by the antiserum was subtracted, and the percent of HGPRT 
activity specifically precipitated by anti-HGPRT serum was determined. 
At least 95% of the HGPRT activity was precipitated in the presence of 
excess anti-HGPRT serum. 
Immunochemical titration was performed in a similar manner except 
that the amount of cell extract was kept constant and the dilution of rabbit 
anti-HGPRT serum was varied from 1/64 to 1/512. Nonimmune serum was 
included to keep the total rabbit serum concentration constant at a 1/64 di- 
lution, and a 89 dilution of goat antirabbit IgG serum was used. 
R E S U L T S  
Sensit ivity to 6TG 
To determine the sensitivity of the cell line MGL8 to the selective 
procedure, cells were cloned at various densities in soft agarose (7) 
containing 6TG at several concentrations. Sensitivity was indicated by 
the proportion of visible colonies formed compared to controls. Figure 1 
shows the results of these experiments. About 4% of the cells survived se- 
lection with 0.3 ~g/ml 6TG. Only rare colonies were found when 1 ~/ml 
was used, and the frequency was not reduced by using 3 /~g/ml of the 
drug. These colonies at 1/~g/ml were formed by preexisting 6TG-resistant 
cells at a frequency of 3 x 10 -6 colonies/cell plated; pretreatment with 
HAT (16, 17) decreased the frequency to a minimum of 3 • 10 -7 
colonies/cell plated. Thereafter we used for selection 6TG at a concentra- 
tion of 1 ~g/ml. 
Albertini and DeMars (18), Orkin and Littlefield (19), and Sato et al. 
(7) have reported that the recovery of rare resistant cells is decreased 
when the cell density in the selection plates is increased. To determine the 
effect of high density of MGL8 cells on the recovery of variants, we first 
obtained a 6TG-resistant variant by selection in mass culture. After 
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l~g. 1. Sensitivity of MGL8 to 6-thioguanine. 3 • 102-1 x 106 cells were plated in soft 
agarose containing 6TG at 0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, and 3 /~g/ml. The cloning 
efficiency in the absence of 6TG was 18%. The percent of surviving colonies corrected for 
cloning efficiency was plotted against drug concentration. For each point 6-10 dishes were 
scored. 
r ecove ry  f rom EMS t r ea tmen t ,  10 ml cul tures  con ta in ing  app rox ima te ly  
5 x 106 cells were refed twice weekly  with R P M I  1640 m e d i u m  con ta in ing  
6TG at 1/xg/ml. After  abou t  3 weeks ,  cell popu la t ions  emerged  that  were  
res i s tan t  to high levels  of  6TG. We used  these  cells for a r e c o n s t r u c t i o n  
expe r imen t  as follows: 300 of the 6TG R cells were  c loned  in 2 ml of  soft 
agarose  con ta in ing  6TG in the p resence  of  0, 5 x 104, 5 x 105, and  1 x 106 
sens i t ive  M G L 8  cells,  and the c loning  efficiencies were  compared .  The  
resul ts  are summar i zed  in Table  1. Based on  these  resul ts  we chose  to use  
a dens i ty  of 5 x 105 cells per  plate  for an  efficient se lec t ion  of  res i s tan t  
cells. 
Table 1. Summary of Results a 
Variant MGL8 Cloning 
cells/plate cells/plate efficiency (s.d.) 
3 x 102 0 8% (1) 
3 x 102 5 x 104 12% (3) 
3 x 102 5 • 105 6% (1.5) 
3 x 102 1 x 10 e 3% (1.3) 
aHGPRT-deficient variant cells, derived from MGL8 by .mass culture selection after 
"mutagenesis," were plated in soft agarose containing 6-thioguanine (1/xg/ml) with MGL8 
cells. For each point 6 replicate plates were scored. 
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Isolation of Variants 
Exponentially growing MGL8 cells were treated with HAT for 6-8 
days. The medium was changed to medium containing adenine (1 x 10 -~ 
M), thymidine (2 x 10 -4 M), and EMS (200/,tg/ml). After 20 hr the culture 
was centrifuged for 10 min at 300g, the medium was discarded, and the 
cell pellet was resuspended in fresh medium to the original volume and 
divided into several 10-ml cultures. Survival was tested by cloning in soft 
agarose, and the recovery pattern was followed by daily cell counts. Dur- 
ing the recovery period the cells were refed every 3 days by replacing one- 
half of the medium with fresh medium. When fully recovered, the cells 
were cloned in soft agarose containing 6TG (1 ftg/ml) at a density of 5 x 
l0 s cells per 60-mm dish. Three to four weeks later all the dishes had 
colonies of various sizes. The frequency of 6TG-resistant colonies was 
increased approximately 16-fold by EMS. From each group of selection 
dishes into which cells had been inoculated from one culture flask, a few 
of the bigger colonies were isolated and propagated into lines. Of these 
only one line, chosen arbitrarily or because of rapid growth, was 
characterized further, in order to assure the use of independently derived 
variant lines. The resulting cultures of 6TG-resistant cells were identified 
as the MGL8A lines (e.g., A18), and were tested to determine the degree 
and nature of their resistance by observing their growth in the presence of 
increasing amounts of 6TG and in HAT medium, as compared to growth 
in regular medium alone. Also the activity of HGPRT was determined for 
all resistant cells, and the presence of HGPRT protein tested by im- 
munochemical assay. 
In all, we measured the growth properties, HGPRT enzyme activity, 
and presence of CRM (immunologically cross-reacting material) in 18 sub- 
lines originating from 18 independently "mutagenized" cultures. 
Enzyme Activity 
The 6TG-resistant lines were subcultures at 2 x 105 cells/ml into me- 
dium containing 6TG at concentration of up to 10 ftg/ml. They grew at 
rates comparable to that of controls subcultured in regular medium. All 
the lines with the exception of A30 were killed by exposure to HAT me- 
dium for 3-5 days. Line A30 did not grow in HAT, but was not killed 
under these conditions even after 30 days of treatment, and could be res- 
cued by removing the HAT and feeding with regular medium. When 
assayed for HGPRT activity, extracts of the normal MGL8 cells showed a 
specific activity of 400 nmoles/mg protein/hr (s.d. 7%). Of the resistant 
lines only the A30 extract had a significantly detectable level of HGPRT 
activity, 4 nmoles/mg protein/hr. Line A29 had a doubtfully significant 
enzyme activity level of 0.5-0.7 nmoles/mg protein/hr, and the activity 
level of the other extracts was lower than 0.1 nmole/mg protein/hr. The 
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HGPRT activity of the cell extracts remained unchanged under the dif- 
ferent assay conditions as specified in the methods, with one exception. 
The activity of A30 alone was increased two-fold when assayed at pH 10. 
This suggests a structural change in the enzyme protein. 
We compared the kinetic behavior of the A30 enzyme to that of 
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Fig. 2. Kinetic behavior  of  H G P R T  in MGL8 and A30 extracts .  Cells were lysed and ex- 
tracts prepared and assayed  for HGP R T  activity as descr ibed in Materials and Methods  sec- 
tion. (a) Double reciprocal plot of  enzyme  activity against  hypoxan th ine  concentrat ion,  e - -  
9 MGL8 ( g  m = 4.5 x 10 -5 M, V m a  x = 2 • 10 -6 mole/mg/hr),  A - - A  A30 (K,, = 1.2 x 10 -4 M, 
Vmax = 7.1 x 10 -s  mole/mg/hr).  (b) and (c) Double reciprocal plots of  H G P R T  activity 
against  concentra t ion of PRPP. The concentra t ion of  Mg § was kept  at 5 t imes that  of  PRPP. 
(b) MGL8 (Kin = 3.1 x 10 -5 M, Vma x x 1.2 x 10 -r mole/mg/hr.){ (c) A30 (K,~ = 6 • 10 -2 M, 
Vmax = 4 • 10 -8 mole/mg/hr).  
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hypoxanthine of 1.2 x 10 -4, compared to 4.5 x 10 -5 M for MGL8. A com- 
parison of the data presented in Figures 2b and 2c shows that the PRPP 
(phosphoribosylpyrophosphate) Km value of A30 is 6 x 10 -2 M, three 
orders of magnitude higher than the corresponding Km value for MGL8, 
3 x 10 -5 M. We further compared the heat stability and the inactivation 
by trypsin of HGPRT in the A30 extract to HGPRT in the MGL8 extract. 
To determine heat inactivation, dialyzed extracts of MGL8 and A30 cells, 
diluted to a protein concentration of 5 mg/ml, were heated at 80~ for 0- 
48 min, chilled rapidly, and centrifuged at 10,000g for 20 min. Then the 
supernatants were assayed for HGPRT activity. Figure 3 shows that the 
extract of A30 loses its HGPRT activity much faster than MGL8. Heating 
at 80~ for 4 min resulted in a loss of 98% of the initial activity, compared 
to a loss of less than 10% of the MGL8 activity. To determine the inactiva- 
tion of HGPRT by trypsin, 100/.tl aliquots of dialyzed extract diluted to a 
protein concentration of 6 mg/ml were incubated with 10 ftl of trypsin 
(Sigma, 3 mg/ml) at 25~ for 0-20 rain. The proteolytic reaction was 
stopped by the addition of 10 ~1 of soybean trypsin inhibitor (Sigma, 6 
mg/ml), and the reaction mixture was assayed for HGPRT activity. As 
Fig, 4 shows, the A30 enzyme was inactivated by trypsin much faster than 
Time, Minutes 
Hg. 3. Heat inactivation os HGPRT activity. Extracts at 5 mg protein/ml were heated at 
80~ for 0-48 min, chilled rapidly, and centrifuged at ]0,000g for 20 rain. The residual 
activities in the supernatant fluids, expressed as percent of the initial activity, were plotted 
against time of incubation, e - - o  MGL8 (initial activity 23,705 cpm); AwA A30 (initial 
activity 650 cpm). 
143 
:~ 5 0 .  
- 4 0  
3 0 -  
2 5 .  
2 0  
Time,Minutes 
Diploid Human Lymphoblast Variants 
I 0 0  
Fig. 4. Trypsin inactivation of HGPRT activity. Extracts at 6 mg protein/ml were incubated 
at 25~ with 10/xl of trypsin (3 mg/ml). The proteolytic reaction was stopped with 10/zl of 
trypsin inhibitor (6 mg/ml). Residual HGPRT activity was plotted against time of incubation. 
o--u MGL8 (initial activity 17,518 cpm). z~__,, A30 (initial activity 493 cpm). 
the wild-type HGPRT.  After 5 rain of incubation, 76% of the A30 activity 
was lost, compared to 41% of the MGL8 activity. In summary,  the 
HGPRT of  th ,~ variant line differed from the enzyme of  the wild-type 
parental line MGL8 in regard to the pH 10/7.4 activity ratio, sensitivity to 
heat, rate of inactivation by trypsin and Km value for PRPP. 
Immunochemicai  Determinations 
Variant cell extracts with markedly reduced or undetectable levels of  
HGPRT activity were examined for the presence of  material cross-react- 
ing immunologically (CRM) to normal HGPRT by the method of im- 
munoprecipitation inhibition. In a standard immunoprecipitat ion reac- 
tion, with constant amounts of  wild-type MGL8 extract  (2.75/zg protein) 
and antiserum (25/zl of  1/512 dilution), 33% of the initial H G P RT activity 
remained unprecipitated. The addition of  increasing amounts  of  wild-type 
extract  resulted in an increase in the percent  of  unprecipitated H G P RT 
activity approaching 100%, which was interpreted as the inhibition of  the 
precipitation capacity of  HGPRT antibody due to antigen excess.  Figure 5 
illustrates the immunoprecipitation-inhibition curves for MGL8 and 6 
representative mutant extracts,  and demonstrates the various different 
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Fig. 5. Demonstration of CRM in mutant cell extracts by immunoprecipitation-inhibition. 
Immunochemical reaction mixtures contained 2.75 ftg of wild-type extract protein, 0.40-500 
pg of additional wild-type or mutant extract protein, and 25 p~l of antiserum or nonimmune 
serum. In the absence of additional extract, supernatant HGPRT activity with nonimmune 
serum (initial activity) was 859 cpm and was reduced to 33% of this value with antiserum. 
For reactions with additional extract the percent of HGPRT activity unprecipitated by anti- 
serum was determined, and the percent value above 33% was plotted versus the amount of 
extract protein added, o--MGL8; ~--A27; Lx--A29; []--A30; N--A31; o--A35; X--A43. 
levels of CRM found in this series of HGPRT-deficient variant cell lines. 
Quantitation of CRM in variant extracts was done by graphic determina- 
tion of the amounts of wild-type and variant extract protein required to 
produce a similar increase in the percent of unprecipitated HGPRT activ- 
ity, followed by calculation of the percent CRM relative to wild-type ac- 
cording to the formula, 
ftg wild-type protein • 100 
fig variant protein 
All experimental points in which there was an increase of at least 7% in 
the residual activity were used to calculate CRM levels. Accurate quanti- 
ration of CRM by this method would require that the shape of the variant 
immunoprecipitation-inhibition curve be closely similar to that of  wild- 
type HGPRT. At least two variant extracts, A29 and A30, yielded curves 
with slightly altered shapes, which contributed some degree of error 
(expressed in s.d., Table 2). As Fig. 5 demonstrates,  when enough of the 
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Table 2. Properties of 6TG-Resistant Mutants 
Cell HGPRT Growth in Killed by CRM 
line nmole/mg hr 6TG (10/zg/ml) HAT % of MGL8 Karyotype 
MGL8 400 - - 46,XY,6p- 
A27 <0.1 + + 1 - 0.2 46,XY,6p- 
A29 0.6 + + 38 -+ 15 46,XY,6p- 
A30 4 a + - 10 -+ 5 46,XY,6p- 
A35 <0.1 + + 4 -+- 1 46,XY,6p- 
Other 14 <0.1 + + <0.6 46,XY,6p- 
aDetermined at 1 mM PRPP; see text and caption to Fig. 2 for Vma x values. 
M G L 8  ex t r ac t  was  added ,  the c o m p e t i t i o n  was  c o m p l e t e  and full 
r e c o v e r y  o f  the initial H G P R T  occur red .  This  is e x p r e s s e d  in Fig.  5 as a 
max ima l  r e c o v e r y  l eve l  o f  67% of  the init ial  ac t iv i ty ,  s ince  33% o f  the 
initial ac t iv i ty  r e m a i n e d  unprec ip i t a ted .  
F o u r  o f  the var ian ts  had signif icantly de t ec t ab l e  leve ls  o f  C R M .  A29 
had abou t  38% and A27 had the l owes t  de t ec t ab l e  level ,  1%. T h e  res t  o f  
the mu tan t  l ines s h o w e d  a v e r y  low leve l  o f  com pe t i t i on ,  de t ec t ab l e  only  
w h e n  v e r y  high v o l u m e s  o f  ex t r ac t  w e r e  added ;  ca l cu la t ed  C R M  va lues  
w e r e  0 . 2 - 0 . 6 %  of  the normal ,  wh ich  in our  a s say  sys t em is no t  significant.  
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Fig. 6. [mmunochemical titration of wild-type and mutant cell HGPRT. [mmunochemical 
reaction mixtures contained either 8.25/Lg of MGL8 (wild-type) extract protein or 82.5/~g of 
A30 (HGPRT-deficient variant) extract protein. The initial HGPRT activities (with nonim- 
mune serum only) for MGL8 and A30 were 2757 and 595 cpm, respectively. Enzyme assays 
were performed as described in Materials and Methods section except that A30 HGPRT was 
assayed in the presence of 10 mM MgPRPP for 2 hr. HGPRT activity unprecipitated by anti- 
serum was expressed as percent of initial activity and plotted versus concentration of anti- 
serum, o-MGL8; A-A30. 
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level of activity, was compared to that of the MGL8 enzyme by a direct 
method of immunochemical titration. Figure 6 shows that when increas- 
ing amounts ot antiserum were added to the cell extracts, the A30 extract 
yielded a precipitation curve very similar to that of the MGL8 enzyme. 
This similarity between the precipitation curves suggests that the HGPRT 
molecules present in the A30 cells have the same antigenicity as MGL8 
HGPRT, and are therefore recognized equally by the anti-HGPRT anti- 
bodies. 
DISCUSSION 
We have treated a diploid human lymphoblast line with EMS and 
selected a series of independent 6TG-resistant clonal sublines. The ability 
to clear the cultures of preexisting HGPRT-deficient cells facilitates the 
selection from separate cultures of variant cells that are the results of in- 
dependent events. 
Phenotype alteration in cells may result from changes other than true 
mutations. These may involve changes in chromosome number, reorgani- 
zation of chromosomes, poorly understood epigenetic processes, and 
other events not related to the primary structure of genes (1-4). All our 
6TG-resistant cells, including lines with or without CRM, maintained the 
Q-banded karyotype of the parent cell line without detectable change. 
Therefore, a presently detectable cytogenetic change did not cause the 
variation. 
The highest residual HGPRT activity measured in the variants was at 
the level of 1% of the normal. This might suggest that the concentration of 
6TG employed for selection was too high to allow survival of cells with 
more residual enzyme activity. However, the A30 cells that showed this 
level of activity could not be killed by HAT, which suggests that a rela- 
tively low level of enzyme activity is required for sufficient phos- 
phoribosylation of hypoxanthine. The maximal velocity of HGPRT 
activity in MGL8 cells, calculated on a cellular basis, is about 105 times 
higher than the maximal rate at which hypoxanthine enters the cells (23). 
Thus transport appears to be rate-limiting in the incorporation of the 
purine base into nucleic acids (23, 24). 6TG must be phosphoribosylated 
by HGPRT in order to exert its toxic effect; and based on what was shown 
for hypoxanthine, we feel that in cells with measurable enzyme activity, 
in which the enzyme's affinity for 6TG is not drastically reduced, the rate 
at which the drug enters the cell determines the effectiveness of the selec- 
tion system. The ,data presented in Fig. 1 indicate that lowering the 
concentration of 6TG in the selection plates decreases the effectiveness of 
the system for the selection of cells resistant to the drug, probably be- 
cause of an uptake barrier. Therefore, when enough 6TG is used to kill all 
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sensitive cells, only mutants with very little or no residual HGPRT 
activity will survive the selection. 
Four of the resistant lines had detectable amounts of CRM. Among 
these A29 showed the highest level of 38%, and A30 retained some 
catalytic activity in addition to 10% CRM. The low levels of CRM in the 
CRM-positive mutants could be explained by high sensitivity to heat or 
trypsin, as is evident in Figs. 3 and 4 for the A30 enzyme. Capecchi et al. 
reported that abnormal HGPRT proteins are selectively degraded in 
CRM-positive variant mouse cells, and that the rates of degradation de- 
termine the concentrations of these proteins in such cells (25). The resid- 
ual HGPRT activity in extracts of A30 was also different from the normal 
in its kinetic behavior and in the pH 10/7.4 activity ratio. All these results 
suggest that A30 has a true mutation in the structural gene for HGPRT. It 
is likely that the other CRM-positive lines also contain structural gene 
mutations, although possibilities such as posttranslation modification can- 
not be excluded at present. 
Altered levels of immunologically reactive material might reflect al- 
tered antigenicity of the variant protein, rather than just the amount of 
enzyme protein present. The experimentsummarized in Fig. 6 suggests 
that for A30 cells this was not the case. When equal amounts of anti- 
genically reactive material of both the normal parent and the variant cell 
line were used, similar precipitation curves were observed. This strongly 
suggests that the antigenicity of the variant protein is similar to that of the 
normal cells, and that the CRM level is a quantitative measure. Also sug- 
gested by the similarity of the two curves is that the residual enzyme 
activity is evenly distributed among the one type of precipitable 
molecules present in the variant cells. 
We have described a series of HGPRT-deficient variants derived in- 
dependently from a diploid human lymphoblast line. Four of these sub- 
lines have various levels of CRM, and one of these retained a significant 
level of enzyme activity, which is different from the enzyme of the 
parental cells by several criteria. The variant sublines retained the Q- 
banded parental karyotype in all their cells. The different characteristics 
of these variants suggest that indeed they result from independent events. 
Such variants should prove valuable for studies on the molecular genetics 
of HGPRT, and also for studies on the regulation of expression of the 
HGPRT gene (26), the role of HGPRT in the transport of purine bases 
(23), and the regulation of purine biosynthesis in general (8, 27). 
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